Renalytix (GB:RENX)
LSE:RENX
Top Page
Renalytix
(LSE:RENX)
Select Model
Select Model
Rating:39Underperform
Price Target:
2.00 p
▼(-66.10% Downside)
Action:DowngradedDate:03/26/26
The score is constrained primarily by weak financial fundamentals (large losses, heavy cash burn, and negative equity). Technicals add further downside risk with a strong downtrend and negative momentum, while valuation is also pressured by ongoing losses and no dividend support.
Positive Factors
Improving revenue and gross margin
Revenue growth and a sizeable gross margin improvement signal that product uptake and pricing are beginning to scale. If sustained, higher margins materially enhance operating leverage, meaning incremental volume converts more directly to profit as commercialization expands over the coming months.
Negative Factors
Large net losses and dependence on funding
Sustained large net losses and ongoing negative cash flow mean the business is dependent on external financing to operate. That reliance can dilute shareholders, distract management with fundraising, and constrain investment in sales and reimbursement required to scale the diagnostic business.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving revenue and gross margin
Revenue growth and a sizeable gross margin improvement signal that product uptake and pricing are beginning to scale. If sustained, higher margins materially enhance operating leverage, meaning incremental volume converts more directly to profit as commercialization expands over the coming months.
Read all positive factors
Renalytix (RENX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£8.52M
Dividend YieldN/A
Average Volume (3M)10.03M
Price to Earnings (P/E)―
Beta (1Y)0.04
Revenue Growth-4.48%
EPS Growth61.09%
CountryUK
Employees102
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.02
Shares Outstanding437,018,680
10 Day Avg. Volume3,807,103
30 Day Avg. Volume10,033,489
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-1.38
Price to Sales (P/S)3.23
P/FCF Ratio-0.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Renalytix Business Overview & Revenue Model
Company Description
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data i...
How the Company Makes Money
Renalytix primarily makes money by commercializing its diagnostic tests, most notably KidneyIntelX, generating revenue when the test is ordered for patients and processed through the company’s testing/laboratory pathway (or an authorized laborator...
Renalytix Earnings Call Summary
Earnings Call Date:May 15, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:Nov 03, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant strategic achievements, including Medicare coverage developments, inclusion in clinical guidelines, successful fundraising, and cost reduction efforts. However, there are challenges such as a decline in revenue and testing volumes, and adoption hurdles in the VA system. The sentiment is balanced, with positive long-term strategic developments countered by short-term operational challenges.Positive Updates
Positive Medicare Coverage Developments
Medicare contractor National Government Services issued a draft local coverage determination for KidneyIntelX, with expectations for a final coverage determination in the near term.
Negative Updates
Revenue Decline
Recorded revenue of $535,000 for Q3 2024, down from $724,000 in the prior year period.
Read all updates
Q3-2024 Updates
Positive
Negative
Positive Medicare Coverage Developments
Medicare contractor National Government Services issued a draft local coverage determination for KidneyIntelX, with expectations for a final coverage determination in the near term.
Read all positive updates
Company Guidance
During the third quarter earnings call for Renalytix (Symbol: RENX.L), management provided a detailed overview of their financial and strategic progress. The company reported a revenue of $535,000 for Q3 2024, with 806 tests processed, 82% of which were billable. This reflects a decline from the previous year, attributed to the conclusion of a $6 million contract with Mount Sinai. Operating expenses were significantly reduced by 40% year-over-year to $6.5 million, following strategic reorganization efforts, including a 50% reduction in headcount. The net loss also decreased by 36% to $7.7 million. The launch of the FDA-authorized KidneyIntelX.dkd product and increased insurance reimbursement were highlighted as key developments. The company emphasized their strategic focus on sales growth with a 33% increase in direct-to-physician test orders quarter-over-quarter, while anticipating further growth with the expected finalization of Medicare coverage and inclusion in international clinical guidelines. Additionally, Renalytix raised $13.5 million in aggregate gross proceeds from recent financings and reported $4.7 million in cash as of March 31, excluding additional financing proceeds. The ongoing strategic review, including potential acquisition interest, was also discussed, though specifics were limited due to regulatory constraints.Renalytix Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Jun 2025 | Sep 2024 | Jun 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.37M | 3.00M | 2.29M | 3.40M | 2.97M | 1.49M |
| Gross Profit | 468.00K | 1.20M | 156.00K | 701.00K | 918.00K | 687.00K |
| EBITDA | -23.07M | -21.30M | -28.52M | -41.71M | -52.69M | -32.69M |
| Net Income | -23.43M | -20.40M | -33.46M | -45.61M | -45.28M | -34.73M |
Balance Sheet | ||||||
| Total Assets | 11.44M | 6.10M | 7.97M | 42.12M | 63.26M | 102.58M |
| Cash, Cash Equivalents and Short-Term Investments | 9.63M | 3.70M | 4.68M | 24.68M | 41.33M | 74.45M |
| Total Debt | 8.21M | 8.30M | 8.54M | 12.15M | 12.34M | 352.00K |
| Total Liabilities | 12.81M | 13.10M | 15.83M | 23.66M | 20.09M | 7.48M |
| Stockholders Equity | -1.37M | -7.00M | -7.85M | 6.97M | 30.61M | 95.10M |
Cash Flow | ||||||
| Free Cash Flow | -23.02M | -17.90M | -30.11M | -32.67M | -46.44M | -26.26M |
| Operating Cash Flow | -23.02M | -17.90M | -30.11M | -32.67M | -45.74M | -24.63M |
| Investing Cash Flow | 18.00K | 0.00 | -4.00K | 0.00 | -694.00K | -741.00K |
| Financing Cash Flow | 26.88M | 16.00M | 10.25M | 16.39M | 25.52M | 77.24M |
Renalytix Technical Analysis
Negative
5.90
Price Trends
3.57
Negative
4.97
Negative
6.22
Negative
Market Momentum
-0.46
Negative
17.13
Positive
8.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:RENX, the sentiment is Negative. The current price of 5.9 is above the 20-day moving average (MA) of 2.44, above the 50-day MA of 3.57, and below the 200-day MA of 6.22, indicating a bearish trend. The MACD of -0.46 indicates Negative momentum. The RSI at 17.13 is Positive, neither overbought nor oversold. The STOCH value of 8.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:RENX.
Renalytix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | £104.06M | 55.78 | 3.01% | ― | -1.43% | 28.57% | |
58 Neutral | £7.19M | -0.39 | -122.54% | ― | -57.03% | -15.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £15.25M | -0.76 | -153.92% | ― | 90.42% | 79.21% | |
42 Neutral | £5.52M | -1.05 | 44.15% | ― | 12.19% | 18.12% | |
40 Underperform | £8.15M | -0.25 | -316.67% | ― | 72.17% | 79.03% | |
39 Underperform | £8.52M | ― | 425.97% | ― | -4.48% | 61.09% |
* Healthcare Sector Average
GB:RENX
Renalytix
1.95
-6.05
-75.63%
GB:EKF
EKF Diagnostics Holdings
24.15
2.55
11.81%
GB:GDR
Genedrive
0.95
-0.57
-37.58%
GB:OBD
Oxford BioDynamics
0.19
-0.23
-54.76%
GB:PRM
Proteome Sciences
1.58
-1.43
-47.67%
GB:VRCI
Verici Dx Plc
0.48
-1.94
-80.37%
Renalytix Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Renalytix Grows Revenue and Integration Footprint as It Pursues National Rollout of KidneyintelX.dkd
Positive
Mar 26, 2026
Renalytix reported first-half FY26 revenues of $1.6 million, up from $1.3 million a year earlier, reflecting growing physician adoption of its kidneyintelX.dkd test and expansion to 58 new practice sites across New York, Texas, Florida and Arizona...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Renalytix Lifts Revenue as KidneyintelX Expansion and Distribution Talks Gather Pace
Positive
Mar 26, 2026
Renalytix reported first-half fiscal 2026 revenues of $1.6 million, up from $1.3 million a year earlier, as it expanded kidneyintelX.dkd deployment to 58 additional practice sites and five fully integrated EHR systems across key U.S. regions. The ...
Business Operations and Strategy
Renalytix CEO Boosts Stake as Kidney Disease Test Rollout Advances
Positive
Feb 13, 2026
Renalytix said Chief Executive James McCullough has increased his stake in the company by purchasing an additional 750 American Depositary Shares at an average price of $3.15 per ADS. Following the latest transaction, he now has an interest in 3,4...
Business Operations and StrategyProduct-Related Announcements
Renalytix CFO Increases Stake as KidneyintelX.dkd Deployment Expands
Positive
Feb 13, 2026
Renalytix plc reported that interim Chief Financial Officer Joel Jung purchased an additional 500 American Depositary Shares at $2.85 per ADS, increasing his holding to 333,855 ordinary shares, or about 0.07% of the company’s issued share ca...
Business Operations and StrategyProduct-Related Announcements
Renalytix CFO Increases Stake as Kidney Disease Test Gains Traction
Positive
Feb 12, 2026
Renalytix announced that interim Chief Financial Officer Joel Jung purchased 2,000 American Depositary Shares at $2.90 per ADS on 11 February 2026, increasing his interest to 308,855 ordinary shares, or about 0.07% of the company’s issued sh...
Business Operations and Strategy
Renalytix CEO Increases Stake Amid Expansion of Kidney Disease Test
Positive
Feb 12, 2026
Renalytix plc announced that Chief Executive Officer James McCullough purchased 3,010 American Depositary Shares of the company on 11 February 2026 at an average price of $3.01 per ADS. Following this transaction, McCullough’s total interest...
Business Operations and StrategyFinancial Disclosures
Renalytix Eyes Revenue Growth as Kidney Diagnostic Expands U.S. Footprint
Positive
Feb 11, 2026
Renalytix reported unaudited first-half fiscal 2026 revenues of $1.6 million and forecast full-year revenue of about $4 million, a 33% increase year-on-year, as it accelerates electronic medical record integrations for its kidneyintelX.dkd test ac...
Business Operations and StrategyProduct-Related Announcements
Renalytix Adds Three U.S. Kidney Care Integrations and Deepens Tempus AI Collaboration
Positive
Jan 12, 2026
Renalytix has expanded the clinical footprint of its kidneyintelX.dkd test in the US by completing three new electronic health record-integrated deployments with regional kidney care providers in New York, Florida and Tennessee, with testing now u...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.